Sapience Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Team
    • Directors
    • Advisors
  • Our Approach
    • Overview
    • Therapeutic Approach
    • Discovery Platform
  • Pipeline
    • Overview
    • ST101
    • β-Catenin Antagonist
    • cJun Antagonist
    • cMyc Antagonist
    • FoxP3 Antagonist
  • Partnering
  • Careers
  • News & Media
    • Press Releases
    • Publications
    • Presentations
    • Email Alerts
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications
  • Presentations
  • Email Alerts
Dec 01, 2020 9:30am EST

Sapience Therapeutics Appoints J. Andrew Sanford to Its Board of Directors

Nov 19, 2020 8:30am EST

Sapience Therapeutics Renews Drug Discovery Pact with the University of Bath

Nov 17, 2020 8:30am EST

Sapience Therapeutics Completes $14 million Preferred Stock Financing

Aug 19, 2020 8:30am EDT

Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute

Aug 12, 2020 8:30am EDT

Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors

Jun 17, 2020 8:30am EDT

Sapience Therapeutics to Present Data on its Two Lead Programs at 2020 AACR Virtual Annual Meeting II

Jun 02, 2020 8:30am EDT

Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications

May 07, 2020 8:30am EDT

Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1/2 Trial of Lead Candidate ST101 in Advanced Cancer Indications

Jan 07, 2020 8:30am EST

Sapience Therapeutics to Present at Biotech Showcase 2020

Oct 29, 2019 8:30am EDT

Sapience Therapeutics to Present at the 2019 Life Sciences Summit

  • 1
  • 2
  • 3
  • Next
RSS
© 2021 Sapience Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap